What is the recommended treatment for insomnia in an adult patient without hepatic or renal impairment and no contraindications?

Insomnia Treatment

For adult patients with chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment, but when pharmacologic therapy is indicated, use eszopiclone (2-3 mg), zolpidem (10 mg), or suvorexant (10-20 mg) for both sleep onset and maintenance insomnia, with treatment selection based on the specific sleep pattern disturbance. 1

Treatment Algorithm

First-Line: Non-Pharmacologic

• CBT-I is the gold standard for chronic insomnia in all adults regardless of age or comorbidities 2
• Can be delivered in-person or digitally with equivalent efficacy 2
• Should be attempted before or alongside pharmacologic therapy

Second-Line: Pharmacologic Options

When CBT-I is insufficient or unavailable, select medications based on insomnia type:

For Sleep Onset Insomnia (Difficulty Falling Asleep):

• Zaleplon 10 mg - specifically for sleep initiation 1
• Ramelteon 8 mg - melatonin receptor agonist for sleep onset 1
• Triazolam 0.25 mg - benzodiazepine option 1
• Zolpidem 10 mg - also effective for maintenance 1
• Eszopiclone 2-3 mg - also effective for maintenance 1

For Sleep Maintenance Insomnia (Frequent Awakenings/Early Morning Awakening):

• Suvorexant 10-20 mg - orexin receptor antagonist, specifically for maintenance 1
• Doxepin 3-6 mg - low-dose tricyclic, specifically for maintenance 1
• Eszopiclone 2-3 mg - effective for both onset and maintenance 1
• Zolpidem 10 mg - effective for both onset and maintenance 1
• Temazepam 15 mg - benzodiazepine for both onset and maintenance 1

Duration of Treatment

• Short-term use preferred: Benzodiazepines and Z-drugs (zolpidem, zaleplon, eszopiclone) should be limited to ≤4 weeks 2
• Longer-term options: Orexin receptor antagonists (suvorexant, daridorexant, lemborexant) can be used for 3-12 months 3, 2
• Older adults (≥55 years): Prolonged-release melatonin can be used up to 3 months 2

Medications to AVOID

The American Academy of Sleep Medicine explicitly recommends against the following 1:

• Trazodone - insufficient evidence despite widespread off-label use
• Diphenhydramine (Benadryl) - anticholinergic effects, next-day sedation
• Melatonin (immediate-release) - insufficient evidence for insomnia treatment
• Tiagabine - anticonvulsant, not effective
• L-tryptophan - insufficient evidence
• Valerian - insufficient evidence

Critical Safety Considerations

All Hypnotics Carry Risks:

• Complex sleep behaviors: Sleep-driving, sleep-eating without recall 4
• Next-day impairment: Memory and psychomotor deficits 4
• Dementia risk: Observational data shows hazard ratio of 2.34 for long-term benzodiazepine/nonbenzodiazepine use 4

Specific Populations:

• Older adults: Avoid Z-drugs due to falls, cognitive impairment, and respiratory depression 5
  • Prefer: Low-dose doxepin, ramelteon, or orexin antagonists 6
• Women: FDA-recommended doses are often lower than studied doses 4
• Respiratory impairment: Avoid Z-drugs; orexin antagonists are safer 5
• Cognitive impairment: Orexin antagonists may be used with mild impairment 5

Advantages of Newer Agents (Orexin Antagonists)

Daridorexant, lemborexant, and suvorexant offer distinct advantages 3:

• Inhibit wakefulness rather than induce sedation
• No evidence of rebound insomnia upon discontinuation
• No withdrawal symptoms
• Minimal to no abuse potential
• Demonstrated efficacy up to 12 months
• Daridorexant has ideal 8-hour half-life 3

Clinical Pearls

• Large placebo response: 24-48% of patients show improvement on placebo, with 19-39 minute improvements in sleep latency and total sleep time 4
• Use as-needed dosing when possible rather than nightly scheduled dosing 5
• Set clear expectations before initiating pharmacotherapy regarding duration and goals 7
• Monitor ongoing: Regular follow-up essential to assess response and adverse effects 7
• Treat comorbidities: Insomnia should be treated as distinct disorder even when occurring with depression or anxiety 3

Strength of Evidence

All pharmacologic recommendations from the American Academy of Sleep Medicine carry WEAK recommendations under GRADE methodology 1. This reflects:

• Industry funding of most trials (publication bias risk)
• Small number of trials per agent
• Heterogeneity in study designs
• Short trial durations (most <4 weeks) 4

This does NOT indicate ineffectiveness, but rather reflects the quality and certainty of available evidence, not the magnitude of treatment effect 1.